Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension

Summary

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial tested the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. The present study investigates effects of valsartan and amlodipine on pre-specified secondary kidney outcomes.

Timeline

Start

1997-09-27

Primary completion

2003-09-05

Completion

2003-12-05

Publications

• Results Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9.
• Olsen E, Soraas CL, Schmieder RE, Jamerson K, MacDonald TM, Mancia G, Heimark S, Mehlum MH, Liestol K, Larstorp ACK, Mariampillai JE, Mo R, Halvorsen LV, Hoieggen A, Rostrup M, Kjeldsen SE, Weber MA. Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients. Am J Hypertens. 2025 Nov 17;38(12):1106-1119. doi: 10.1093/ajh/hpaf093.

Drugs

Indications